.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Healthtrust
Daiichi Sankyo
Merck
McKinsey
Fish and Richardson
Queensland Health
UBS
Novartis

Pharmaceutical companies with the most 'Antibiotic GAIN Act' drugs

This chart shows the companies which have received the most GAIN Act exclusivities in the past five years.

The Generating Antibiotic Incentives Now Act provides for five years of market exclusivity for qualifying drugs.

The law defines qualifying drugs as 'an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections.'

Unlike most other regulatory extensions, which provide exclusivity starting from a drug's approval date, GAIN Act exclusivity provides an additional five years on top of any Hatch-Waxman exclusivity — even pediatric exclusivity, which extends an additional six months beyond patent protection.

The companies with the GAIN Act exclusivities are:

Back to Pharmaceutical Industry Infographics

For more information try a trial or see the plans and pricing

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot